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Abstract: Background: The Wetterling alcohol withdrawal syndrome (AWS) scale determines withdrawal
severity and guides treatment. We investigated associations between maximum AWS scores and clinical
outcomes. Methods: This retrospective cohort study considered AWS assessments measured from 8/2015-
8/2017. We used multivariable linear and logistic regression to analyze associations between the maximum
score and increased length of stay (LOS) and in-hospital mortality, respectively. Firstly, we investigated
the maximum score of all AWS assessments any time during the stay, secondly, the maximum measured
only within the first 3 days of withdrawal. Results: A total of 2,464 hospital stays showed that, patients
with “mild” (<6), “moderate” (6–9), and “severe” (>9) maximum scores had median LOS of 5.93, 9.35,
14.71 days, mortality was 1.7%, 4.8%, 8.0%, respectively. Regression showed that a higher maximum
score was independently associated with increased LOS and mortality (both p < 0.001). Based on the
maximum AWS score within the first 3 days, the median LOS was 6.18, 9.00, 12.89 days, mortality
was 2.2%, 3.6%, 7.6%, respectively. A higher maximum score in the first 3 days was independently
associated with increased LOS (p = 0.036) and mortality (p = 0.001). Severe maximum AWS scores
within 3 days of withdrawal had an odds ratio of 2.53 (95% CI: 1.27, 4.82; p = 0.0060) for in-hospital
death. Conclusions: Maximum AWS scores associate independently with increased LOS and in-hospital
mortality. This association is reproducible within the first 3 days of withdrawal. Development of such
a 3-day tool could help clinicians assess the risk of worse clinical outcomes early on and adjust care
accordingly.
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Background: The Wetterling alcohol withdrawal syndrome (AWS) scale determines 
withdrawal severity and guides treatment. We investigated associations between maximum 
AWS scores and clinical outcomes.  
Methods: This retrospective cohort study considered AWS assessments measured from 
8/2015-8/2017. We used multivariable linear and logistic regression to analyze associations 
between the maximum score and increased length of stay (LOS) and in-hospital mortality, 
respectively. Firstly, we investigated the maximum score of all AWS assessments any time 
during the stay, secondly, the maximum measured only within the first 3 days of withdrawal.  
Results: A total of 2,464 hospital stays showed that, patients with “mild” (<6), 
“moderate” (6-9), and “severe” (>9) maximum scores had median LOS of 5.93, 9.35, 14.71 
days, mortality was 1.7%, 4.8%, 8.0%, respectively. Regression showed that a higher 
maximum score was independently associated with increased LOS and mortality (both 
p<0.001).  
Based on the maximum AWS score within the first 3 days, the median LOS was 6.18, 9.00, 
12.89 days, mortality was 2.2%, 3.6%, 7.6%, respectively. A higher maximum score in the 
first 3 days was independently associated with increased LOS (p=0.036) and mortality 
(p=0.001). Severe maximum AWS scores within 3 days of withdrawal had an odds ratio of 
2.53 (95% CI: 1.27, 4.82; p=0.0060) for in-hospital death. 
Conclusions: Maximum AWS scores associate independently with increased LOS and 
in-hospital mortality. This association is reproducible within the first 3 days of withdrawal. 
Development of such a 3-day tool could help clinicians assess the risk of worse clinical 
outcomes early on and adjust care accordingly.  
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Alcohol Use disorder (AUD) is a diagnosis given to patients who drink excessive 
amounts of alcohol over longer periods of time leading to cravings,  physical and mental health 
problems, social maladaptation, poor medication adherence, loss of productivity, economic 
loss and psychiatric comorbidity (Grant et al., 2015; Hasin et al., 2007). Consumption of more 
than 100 g/week (5-6 glasses of wine) alcohol is associated with many subtypes of 
cardiovascular diseases, such as stroke, coronary disease and heart failure, and with an 
increased risk of all-cause mortality (Wood et al., 2018). It is reported that up to 40% of  
hospitalized patients as well as up to one third of  patients being admitted to ICU suffer from 
this disorder (de Wit et al., 2010). Management of this disorder includes withdrawal and then 
lifelong abstinence or reduction of consumption (Litten et al., 2016).  
Alcohol withdrawal syndrome (AWS) occurs when abruptly terminating alcohol 
consumption (Jesse et al., 2017). Symptoms of AWS include anxiety, agitation, tremors, 
insomnia, tachycardia, hypertension, and in severe cases hallucinations, confusions, seizures 
and cardiac arrhythmias (Wetterling et al., 2006), in which the gold standard of treatment is 
Benzodiazepines (Sachdeva et al., 2015). Symptoms of AWS need to be monitored to assess 
AWS severity and guide treatment. One instrument facilitating such assessments is the 
Wetterling AWS scale (Wetterling et al., 1997), a validated scale (Williams, 2001). 
Research on AWS is often overshadowed by the focus of public health (Room et al., 
2005) on the epidemiology of alcohol use and its prevention (Axley et al., 2019). The limited 
prior literature has identified clinical variables contributing to AWS severity such as injury 
severity, hypokalemia and delirium tremens (Moore et al., 2017). AWS is known to be 
associated with worse clinical outcomes (Monte et al., 2010) and it substantially increases the 
length of stay (LOS) (Jesse et al., 2017; Salottolo et al., 2017). Factors determining AWS 
 
survival include the number of comorbidities and clinical manifestation (Monte et al., 2010). 
Patients who suffer multiple withdrawals and relapses are known to go through a process called 
kindling, in which there is progressive worsening of symptoms with each detoxification 
(Modesto-Lowe et al., 2005). Most publications on AWS, however, do not consider important 
confounders such as traumatic injuries, cirrhosis or differential diagnostics in their analysis. 
Further confusion arises from a variety of different, sometimes unreliable and invalidated, 
AWS assessment scales (Williams, 2001), obstructing standardized and cooperative research. 
To the best of our knowledge, no study has investigated alcohol withdrawal with a large 
sample size in the context of the clinical meaning of the maximum Wetterling AWS score. We 
therefore analyzed whether the maximum AWS score associates with worse clinical outcomes, 





2.1 Design, setting and study period 
This retrospective cohort study was conducted at the University Hospital Zurich, a 
tertiary care academic medical center, which has approximately 850 beds and around 40,000 
hospital stays a year. Our dataset was derived from electronic health records (EHR), i.e., 
routinely and prospectively collected data. The electronic version of the Wetterling AWS scale 
was introduced at our institution in 08/2015, thus all records from this time point on through 
to 08/2017 were considered. 
The investigation used completely anonymous data and conforms to both local law as 
well as the ethical review and research policies of the University Hospital Zurich. Our study 
adhered to STROBE guidelines (STrengthening the Reporting of OBservational studies in 
Epidemiology) (von Elm et al., 2007). 
 
2.2 Population 
We included all inpatients, aged ≥18, hospitalized in any clinical unit, who had 
undergone at least one AWS assessment with a respective entry in their EHR.  
 
2.3 Wetterling Scale  
The Wetterling Scale (Wetterling et al., 1997) is an 11-item scale in which somatic 
features (pulse rate, diastolic blood pressure, temperature, breathing rate, sweating, and tremor) 
and mental features (agitation, contact, orientation, hallucinations, and anxiety) are assessed to 
make the AWS quantifiable. It was developed by exclusively taking variables from  the CIWA 
(Clinical Institute Withdrawal Assessment for Alcohol) scale with a Cronbach’s α > 0.8 
(Williams, 2001). The inter-rater reliability (κ value) for the scale was determined as 0.64. The 
authors emphasized the easy administration for trained personnel (Wetterling et al., 1997). Of 
 
note, the Wetterling Scale is one of the few validated scales which also includes blood pressure, 
pulse and temperature, not only for the overall assessment, but also in the scale itself (Williams, 
2001).  
 
2.4 AWS assessments  
Our hospital is an alcohol-free institution and does not serve patients alcoholic 
beverages during their stay. AWS assessments are performed by nurses per the institution’s 
Standard Operating Procedures if AUD is suspected and diagnosed. AUD is diagnosed by 
means of the CAGE questionnaire (Ewing, 1984) within 24h of admission, under consideration 
of the medical history, laboratory tests and the diagnosis list. 
One AWS assessment usually takes less than 15 minutes. AUD Patients can have 
multiple assessments, depending on changes in their condition and symptom severity. The 
minimum is one assessment per day in patients with very mild AWS. 
Nurses are trained in the assessment methodology and in the recording of the vegetative 
and psychological symptoms (suggestive questioning). The AWS assessment is always 
accompanied by a Delirium Observation Scale (DOS) assessment (Boettger et al., 2017), which 
helps physicians and nurses better capture mental symptoms. All those processes are 
standardized. In this study, the beginning of withdrawal was defined as the time point of the 
first AWS assessment.  
  
 
2.5 Outcomes and measures 
We analyzed potential associations of the maximum AWS score with worse clinical 
outcomes, i.e., increased LOS and in-hospital mortality, using multivariable linear and logistic 
regression, respectively.  
 As a first step, we included all AWS scores over the entire course of the hospital stay. 
However, we only considered the highest AWS value measured during a patient’s 
stay, which was the maximum AWS score per definition.  
 For the second step, we restricted the AWS values to those assessed within the first 
three days of withdrawal, beginning with the first assessment. We considered the 
highest measured value in this three-day period only. Associations with such a “three-
day maximum AWS score” could be helpful to clinical decision making. 
 
2.6 Exposure 
The exposure of interest was the maximum measured AWS score per patient stay. The 
AWS scale measures vegetative and psychopathological symptoms. Vegetative symptoms 
include pulse rate, diastolic blood pressure, temperature, respiratory rate, sweating, and tremor. 
The mental symptoms include agitation, anxiety, tactile disturbance, disorientation, and 
hallucinations. Each of these symptoms contribute to the AWS assessment scale, leading to 
different scores and an increasing severity of the AWS (Jesse et al., 2017). In our main 
analyses, we considered the maximum score as a continuous variable. 
The scores are categorized into “mild” (<6), “moderate” (6-9), and “severe” (>9) AWS 
states (Wetterling et al., 1997). By using this categorization, we stratified patient characteristics 
and illustrated the strength of associations of maximum AWS scores according to their severity 




Co-variables were selected based on a prior knowledge and the medical literature (Jesse 
et al., 2017). We adjusted for age, sex, marital status, pneumonia (ICD-10 diagnosis codes 
J13*-J18* [International Classification of Diseases, WHO, Geneva, Switzerland; asterisk 
means zero or more digits]), hyponatremia (E87.1), head injuries (S00*-S02*, S06*-S09*), 
depression, chronic heart failure, chronic pain, decompensated liver cirrhosis and diabetes 
(Tonelli et al., 2015). We additionally controlled for general multimorbidity severity by 
adjusting for the number of diagnoses (Sharabiani et al., 2012), since the maximum AWS score 
measured tended to be higher in patients with higher diagnosis counts, which had similarly 
been reported about in its predecessor, the CIWA scale (Duby et al., 2014). 
 
2.8 Data processing and statistical analysis 
Routinely and prospectively collected EHR data were extracted from the clinical data 
warehouse, exported to raw data files, which in turn were imported into a separate database 
management. We used structured query language (SQL) statements to manage that database as 
well as to process the data so that only minor data processing steps were necessary during 
statistical analysis. 
The AWS severity categories were used to stratify patient characteristics. Moreover, 
we additionally stratified the data by sex (Supplementary Table ST12) as recommended 
(Institute of Medicine (US) Committee on Women’s Health Research, 2010). 
Comparative statistical analysis was performed to describe patient characteristics according to 
their maximum AWS score severity category. We used Kruskal-Wallis tests to compare the 
distributions of continuous variables between groups and Fisher’s exact tests to compare 
categorical variables. 
                                                 
 
 
We computed adjusted multivariable linear and logistic regression models to analyze potential 
associations of the maximum AWS score with increased LOS and in-hospital mortality, 
respectively. 
We conducted all tests as 2-sided and determined p-values of ≤0.05 to be indicative for 
statistical significance. Statistical analyses were performed using the software R, version 
3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). 
 
3. Results 

















Figure 1. Study flow diagram. 
 
Considering only the first AWS assessment per hospital stay, 82.2% of first assessments were 
performed within three days after admission into hospital care (878 stays had their first 
assessment on day one; 881 stays on day two; 267 stays on day three; 438 stays on day four or 
later). The median for the first assessment was day 2 (IQR: 1, 3). Of the first measured AWS 
 
scores (median: 2; IQR: 0, 4), 2,036 ranked as mild (82.6%), 322 as moderate (13.0%) and 106 
(5.2%) as severe. 
The median maximum AWS score was 3 (IQR: 1, 6) and was usually reached on the 
third day (median: 3 IQR: 2, 5). Stratification by maximum AWS score resulted in 1,754 mild 
cases (71.2%), 435 moderate cases (17.7%), and 275 severe cases (11.2%). Detailed patient 
characteristics are shown in Table 1. 
 
 
Table 1    Baseline characteristics mild, moderate and severe AWS maximum score (AWS stays n = 2,464)  
Variable               mild          moderate            severe p 
n° (%) 1754 (71.1) 435 (17.6) 275 (11.1)  
Age (median, IQR) 61.00 [50.00, 70.00] 61.00 [51.00, 71.00] 59.00 [50.00, 70.00] 0.756 
BMI (mean, SD)  25.59 (14.58) 26.89 (20.66) 25.00 (4.49) 0.496 
Sex (n, %)    
0.171     Male 1359 (77.4) 334 (76.7) 226 (82.1) 
    Female 395 (22.5) 101 (23.2) 49 (17.8) 
Marital status (n, %)    
0.111 
   married/partner 631(36.0) 141(32.4) 82 (29.8) 
   Single 557 (31.8) 136 (31.3) 97 (35.3) 
   widowed/divorced/separated 465 (26.5) 131 (30.1) 71 (25.8) 
   unknown/other 101(5.8) 27 (6.2) 25 (9.1) 
Died during Stay (n, %)  29 (1.7) 21 (4.8) 22 (8.0) <0.001 
LOS (median, IQR) 5.93 [2.91,11.11] 9.35 [4.88, 17.30] 14.71 [7.47, 23.72] <0.001 
AWS (median, IQR) 3.00 [1.00, 4.00] 7.00 [6.00, 8.00] 12.00 [11.00, 15.00] <0.001 
BAC (median, IQR)  50.65 [34.88, 68.03] 47.80 [30.80, 66.60] 51.60 [26.40, 70.14] 0.772 
Alcohol level in permille (median, 
IQR)  
2.30 [1.60, 3.10] 2.20 [1.40, 3.10] 2.40 [1.30, 3.20] 0.799 
n° Diagnosis (median, IQR) 7.00 [4.00, 10.00] 9.00 [6.00, 14.00] 12.00 [8.00, 18.00] <0.001 
Pneumonia (n, %) 54 (3.1) 31 (7.1) 27 (9.8) <0.001 
Hyponatremia (n, %) 88 (5.0) 35 (8.0) 28 (10.2) 0.001 
Head injuries (n, %) 313 (17.8) 69 (15.9) 53 (19.3) 0.471 
Depression (n, %)  181 (10.3) 48 (11.0) 30 (10.9) 0.865 
Chronic Heart Failure (n, %) 80 (4.6) 38 (8.7) 29 (10.5) <0.001  
Chronic Pain (n, %) 74 (4.2) 16 (3.7) 7 (2.5) 0.421 
Diabetes (n, %)  204 (11.6) 56 (12.9) 31 (11.3) 0.727 
CPD (n, %)  153 (8.7) 42 (9.7) 29 (10.5) 0.531 
Cirrhosis (n, %)  123 (7.0) 38 (8.7) 42 (15.3) <0.001 
ALT (median, IQR)  21.00 [14.00, 34.00] 20.00 [13.00, 47.25] 21.00 [13.00, 40.00] 0.691 
AST (median, IQR)  28.00 [21.00, 48.00] 33.00 [21.00, 101.00] 37.00 [23.50, 105.00] <0.001 
GGT (median, IQR)  72.00 [31.00, 155.75] 104.00 [37.00,182.25] 112.00 [43.00,182.00] <0.001 
BMI = body mass index; LOS = length of stay; CPD = Chronic pulmonary disease; ALT = alanine-aminotransferase;   
AST = aspartate aminotransferase; GGT = Gamma-Glutamyl transferase;   
n BMI = 1042 ; n Died during stay = 72 ; n BAC = 428 ; n  Alcohol level in permille = 412 ; n pneumonia = 112 ; n hyponatremia = 151 ;  
n head injuries = 435;  n depression = 259 ; n chronic heart failure = 147 ; n chronic pain = 97 
 n diabetes = 291 ; n CPD = 224 ; n cirrhosis = 203 ; n ALT = 2008 ; n AST = 1751 ; n GGT = 1618 
 
Figure 2 illustrates that patients with multiple diagnoses had higher maximum AWS 
scores compared to those patients with only few diagnoses. In other words, multimorbid 
patients were at risk for higher maximum AWS scores. It was therefore important that our 
regression models additionally controlled for the number of diagnoses. 
 
Figure 2. This figure illustrates that patients with multiple diagnoses (right-hand side) showed 
higher maximum AWS scores compared to those patients with only few diagnoses (left-hand 
side). In other words, multimorbid patients were at risk for higher maximum AWS scores. It 
was therefore important that our regression models additionally controlled for the number of 
diagnoses.  
Maximum AWS score, LOS and death 
Patients with mild, moderate, and severe maximum AWS scores had a median LOS of 
5.93, 9.35, 14.71 days, and 1.7%, 4.8%, 8.0% patients died during their stay, respectively. 
 
Multivariable regression showed that this was independent of other variables entered into the 
model (Table 2). 
When using the severity groups instead of the continuous variable, the same analysis 
resulted in an increased LOS of 1.41 days (95% confidence interval [CI]: 0.49, 2.33; p=0.0027) 
and 2.53 days (95% CI: 1.39, 3.67; p<0.001) for moderate and severe AWS according to the 
maximum score, respectively. The odds ratios for in-hospital mortality were 2.17 (95% CI: 
1.15, 4.00; p=0.015) and 3.17 (95% CI: 1.65, 6.00; p<0.001) for moderate and severe maximum 
scores, respectively. 
Table 2    Multivariable regression models for LOS and in-hospital mortality considering the continuous variable of the 
maximum AWS score during the entire hospital stay. 
 LOS  in-hospital mortality  
variable  estimate CI  p value  OR CI  p value  
Maximum AWS score  0.271 0.184 ; 0.358 < 0.001 1.098 1.044 ; 1.152 < 0.001 
Age -0.003 -0.030 ; 0.024 0.830 1.056 1.032 ; 1.082 < 0.001 
Sex  0.127 -0.703 ; 0.958 0.764 0.920 0.477 ; 1.679 0.793 





    other/unknown  -1.126 -2.611 ; 0.360 0.138 1.035 0.325 ; 2.715 0.948 
    single  -0.462 -1.356 ; 0.432 0.311 0.963 0.467 ; 1.927 0.917 
   widowed/divorced/separated  -0.865 -1.745 ; 0.014 0.054 1.289 0.703 ; 2.350 0.408 
number of Diagnoses  1.136 1.066 ; 1.205 < 0.001 1.074 1.037 ; 1.112 < 0.001 
Pneumonia 4.236 2.488 ; 5.984 < 0.001 1.191 0.520 ; 2.545 0.665 
Hyponatremia -1.083 -2.529 ; 0.363 0.142 1.119 0.476 ; 2.377 0.783 
Head injuries  -4.515 -5.432 ; -3.598 < 0.001 0.513 0.205 ; 1.120 0.122 
Depression -1.090 -2.214 ; 0.035 0.058 0.936 0.363 ; 2.080 0.880 
Chronic heart failure -1.196 -2.731 ; 0.339 0.127 0.868 0.380 ; 1.844 0.724 
Chronic Pain  -0.754 -2.511 ; 1.003 0.400 3.117 1.244 ; 6.946 < 0.001 
Cirrhosis  -0.042 -1.398 ; 1.314 0.952 4.407 2.220 ; 8.623 < 0.001 
Diabetes  -1.321 -2.408 ; -0.235 0.017 0.935 0.464 ; 1.772 0.842 
CI = confidence interval, OR = Odds Ratio    
 
Maximum AWS score within the first three days of withdrawal, LOS and death 
The maximum AWS scores within the first three days of withdrawal were considered. 
Patients with mild, moderate, and severe maximum AWS scores within the first three days of 
withdrawal had a median LOS of 6.18, 9.00, 12.89 days, and 2.2%, 3.6%, 7.6% died over the 
 
course of the hospitalization, respectively. Again, a higher maximum AWS score within the 
first 3 days of withdrawal was independently associated with increased LOS and mortality 
(Table 3). 
Using the severity groups instead of the continuous variable, the same methods of 
analysis resulted in statistically insignificant increases of the LOS by 0.23 days (95% CI: -0.72, 
1.19; p=0.63) and 0.78 days (95% CI: -0.45, 2.01; p=0.21) for moderate and severe AWS, 
respectively. While the odds ratio for in-hospital mortality was 1.22 (95% CI: 0.61, 2.33; 
p=0.55) for moderate maximum AWS scores, we found that a severe maximum AWS score 
had an increased odds ratio of 2.53 (95% CI: 1.27, 4.82; p=0.0060) for in-hospital death when 
assessed within the first three days of withdrawal. 
Table 3    Multivariable regression models for the outcomes LOS and in-hospital mortality, analyzing the independent 
association with the continuous variable of the maximum AWS score assessed within the first three days of withdrawal. 
 LOS  in-hospital mortality  
variable estimate CI p value OR  CI  p value  
Maximum AWS score in first 3 days 0.098 0.006 ; 0.190 0.036 1.095 1.036 ; 1.155 0.001 
Age -0.005 -0.032 ; 0.022 0.720 1.056 1.032 ; 1.082 < 0.001 
Sex  0.074 -0.762 ; 0.90 0.863 0.913 0.473 ; 1.668 0.776 





   other/unknown  -0.970 -2.466 ; 0.523 0.204 1.041 0.326 ; 2.738 0.939 
   single  -0.378 -1.277 ; 0.522 0.411 1.011 0.491 ; 2.017 0.976 
   widowed/divorced/separated  -0.820 -1.706 ; 0.066 0.070 1.268 0.692 ; 2.301 0.438 
number of Diagnoses  1.180 1.112 ; 1.249 < 0.001 1.079 1.043 ; 1.117 < 0.001 
Pneumonia 4.201 2.442 ; 5.961 < 0.001 1.108 0.478 ; 2.397 0.802 
Hyponatremia -0.956 -2.412 ; 0.499 0.198 1.170 0.498 ; 2.486 0.700 
Head injuries  -4.604 -5.527 ; -3.682 < 0.001 0.503 0.199 ; 1.094 0.109 
Depression -1.144 -2.276 ; -0.012 0.048 0.881 0.340 ; 1.967 0.775 
Chronic heart failure -1.273 -2.818 ; 0.273 0.106 0.839 0.367 ; 1.781 0.661 
Chronic Pain  -0.982 -2.750 ; 0.787 0.277 3.059 1.225 ; 6.800 < 0.001 
Cirrhosis  -0.120 -1.487 ; 1.246 0.863 4.12 2.326 ; 9.007 < 0.001 
Diabetes  -1.480 -2.574 ; -0.387 0.008 0.908 0.452 ; 1.718 0.777 





In this study, we found that the maximum AWS score was independently associated 
with increased LOS and in-hospital mortality. We used adjusted multivariable linear and 
logistic regression models to analyze potential associations between the maximum AWS scores 
and these clinical outcomes. These findings were also found to be reproducible when 
considering only the first three days after start of alcohol withdrawal. Furthermore, a severe 
AWS score (10 or higher) measured within the first three days of withdrawal was statistically 
significantly associated with a 2½-fold increase in the odds of in-hospital death. 
  Alcohol withdrawal begins within several hours after the last alcohol intake depending 
on the severity of the AUD. The most serious symptoms can peak at 24 hours or prolong up to 
several days after the last consumption (Stobart Gallagher and Gomez, 2018). Our study shows 
that higher AWS scores associate with increased mortality as AWS is known to be linked with 
worse clinical outcomes (Monte et al., 2010; Salottolo et al., 2017). As corroborated by our 
results, severe AWS is associated with symptoms, which may occur several days after the 
beginning of withdrawal, such as delirium tremens (Moore et al., 2017) and increases the 
patients’ LOS (Jesse et al., 2017).  
Alcohol (ethanol) is a central nervous system depressant, which triggers an adaptive 
process and the molecular changes associated with tolerance leading to imbalance of excitation 
and inhibition (Olsen and Spigelman, 2012). This molecular change in network leads to a wide 
range of complications, such as a neuroexcitatory effect, that plays an important role in AWS 
and may contribute to increased LOS and mortality (Connor et al., 2016; Hammond et al., 
2017).  
Patients with AUD may be overseen in the initial screening process, as CAGE has been 
criticized for its inability to detect AUD in some age groups (Larimer and Cronce, 2002). This 
may lead to delayed treatment of patients with AWS and worse clinical outcomes. Furthermore, 
 
it may be difficult to identify AWS patients with comorbidities mimicking AWS, potentially 
leading to delayed diagnosis and worse outcomes. 
Our results show a substantial increase of aspartate transaminase (AST) and gamma-
glutamyltransferase (GGT) liver values found in patients with greater AWS severity 
classification, corroborating previous findings (Botros and Sikaris, 2013). The change in the 
aspartate transaminase/alanine transaminase ratio (AST/ALT ratio) and GGT values are 
indicators for severe liver damage, which was confirmed by a substantially increased number 
of patients with cirrhosis in the higher AWS categories (Botros and Sikaris, 2013). AST, ALT, 
GGT markers are easily measured and inexpensive, but their predictive value is limited due to 
low specificity (Jesse et al., 2017). Alcoholic cardiomyopathy is a common diagnosis found 
among chronic alcoholics and may explain the increased proportion of chronic heart failure in 
patients with greater AWS severity classification (Guzzo-Merello et al., 2014). The rate of 
morbidity due to infections, cardiopulmonary insufficiency and bleeding disorders is known to 
be greater in chronic alcoholics (Maldonado et al., 2015). 
Our study supports the introduction and routine use of the Wetterling AWS scale in 
hospital settings in a standardized manner. We used routinely prospectively collected EHR data 
to investigate a large cohort of inpatients undergoing alcohol withdrawal, analyzing nearly 
20,000 AWS assessments, after its implementation in 2015. No stays were excluded if the 
patient had at least one valid AWS assessment, increasing the generalizability of our study. 
The Wetterling AWS score assessments do not account for multimorbidity, which may bias 
the AWS assessment results. Future studies should therefore consider comorbidities and the 
number of diagnoses a patient has. Patients with comorbidities and/or higher diagnosis counts 
may present higher unwarranted AWS scores and it is yet to be tested if this lack of 
consideration may lead to suboptimal treatment. The predecessor of the AWS scale, the CIWA 
scale, was found to confound with comorbidities such as trauma and critical illnesses (Duby et 
 
al., 2014). Based on our findings that the maximum AWS score tends to increase with diagnosis 
count and appears to be subjected to the same limitation as CIWA (Figure 2.). We therefore 
used adjusted regression models, controlling for age, sex, marital status, diagnosis count and 
important comorbidities. 
This study has several strengths. We considered a large sample of hospital stays and 
AWS assessments. The maximum AWS score is an innovative marker indicating worse clinical 
outcomes. The Wetterling scale is a validated scale for AWS (Williams, 2001). The findings 
of this study can be adapted to different clinical settings and translated to benefit practitioners 
and guide future treatment. We believe our findings will contribute to the still limited literature 
concerning AWS and be a first step towards more effective and personalized patient treatment.   
However, the limitations of the study need to be taken into account when interpreting 
our results. This was a single center study. While we did conduct retrospective analyses of 
EHR data, these data were still routinely and prospectively collected. Our definition of the 
comorbidities was based on ICD-10 codes added by professional coders to the diagnosis lists 
after the patients are discharged. This coding procedure does not allow for analysis of changes 
over time of severity of comorbidities during hospital stay. And whereas we had data on only 
the final score result per AWS assessment, there was no information available on the different 
vegetative and psychopathological subcategories of the Wetterling assessment. 
We found that the introduction of a 3-day timeframe for the considerations of the 
maximum scores measured within this period, was sufficient to show associations with 
increased LOS and in-hospital mortality independent of the remaining AWS assessments. 
These maximum AWS values within three days of withdrawal may help health care providers 
to adjust their treatment and to anticipate AWS progression. 
Considerations for future studies include validations of our results and prospective 
evaluations. In this context, an electronic reminder could automatically calculate the maximum 
 
AWS score after a timeframe of three days starting with the first AWS score entry, and studies 
could investigate the value of predictive abilities of such clinical decision support. Whether the 
associations identified in this work are transferable to other AWS assessment scales or other 
unrelated assessments, e.g. delirium scores, are further unanswered questions that could be 
addressed. 
In summary, the data derived from our large cohort were in line with the literature, and 
importantly, maximum AWS scores were associated with worse clinical outcomes in terms of 
LOS and mortality. 
 
5. Conclusions 
Higher maximum AWS scores are associated with increased LOS and in-hospital 
mortality. Determination of the maximum AWS score within 3 days after the first assessment 
appears to be sufficient and may predict increased LOS and in-hospital mortality. This may 
help health care providers to anticipate AWS progression and in properly preparing short-, 
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 Maximum alcohol withdrawal syndrome (AWS) score is higher in multimorbid 
patients. 
 Higher maximum AWS scores associate with worse outcomes (length of 
stay/mortality). 
 Those findings are reproducible already within the first 3 days of withdrawal. 
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Supplementary Table ST1    Baseline characteristics stratified by sex (AWS stays n = 2,464)                               
Variable               male                female p 
n (%) 1919 (77.8) 545 (22.1)  
BMI  (mean, SD) 25.92 (11.04) 25.28 (24.31) 0.569 
Age (median, IQR) 60.00 [50.00,71.00] 61.00 [51.00, 70.00] 0.355 
Marital status (n, %)   
<0.001 
 
    married/partner 712 (37.1) 142 (26.1) 
    single 628 (32.6) 162 (29.6) 
    widowed/divorced/separated 452 (23.7) 215 (39.4) 
    unknown/other 127 (6.6) 26 (4.8) 
Died during Stay (n, %)  57 (3.0) 15 (2.8) 0.886 
LOS (median, IQR) 6.97 [3.17, 13.68] 7.09 [3.37, 13.54] 0.679 
AWS (median, IQR) 3.00 [1.00, 6.00] 3.00 [1.00, 6.00] 0.514 
    Mild (n, %) 1359 (70.8) 395 (72.5) 
0.177     Moderate (n, %) 334 (17.4) 101 (18.5) 
    Severe (n, %) 226 (11.8) 49 (9.0) 
BAC (median, IQR)  50.20 [30.83, 67.60] 53.30 [34.10, 71.50] 0.769 
Alcohol level in permille (median, IQR)  2.30 [1.50, 3.10] 2.50 [1.60, 3.25] 0.824 
n Diagnosis (median, IQR) 8.00 [5.00, 12.00] 8.00 [5.00, 12.00] 0.371 
Pneumonia (n, %) 90 (4.7) 22 (4.0) 0.562 
Hyponatremia (n, %) 107 (5.6) 44 (8.1) 0.042 
Head injuries (n, %) 329 (17.1) 106 (19.4) 0.226 
Depression (n, %)  172 (9.0) 87 (16.0) <0.001 
Chronic Heart Failure (n, %) 117 (6.1) 30 (5.5) 0.682 
Chronic Pain (n, %) 71 (3.7) 26 (4.8) 0.262 
Diabetes (n, %)  247 (12.9) 44 (8.1) 0.002 
CPD (n, %) 174 (9.1) 50 (9.2) 0.867 
Cirrhosis (n, %)  157 (8.2) 46 (8.4) 0.726 
ALT (median, IQR)  22.00 [14.00, 39.00] 19.00 [13.00, 29.00] <0.001 
AST (median, IQR)  30.00 [21.00, 64.00] 29.00 [20.00, 51.00] 0.056 
GGT (median, IQR)  100.50 [35.00,167.25] 69.00 [27.00, 155.00] 0.002 
 
BMI = body mass index; LOS = length of stay; CPD = Chronic pulmonary disease; ALT = alanine-aminotransferase;   
AST = aspartate aminotransferase; GGT = Gamma-Glutamyl transferase;   
n BMI = 1042 ; n Died during stay = 72 ; n BAC = 428 ; n Alcohol level in permille = 412 ; n pneumonia = 112 ; n hyponatremia 
= 151 ; n head injuries = 435; n depression = 259 ; n chronic heart failure = 147 ; n chronic pain = 97 
 n Diabetes = 291 ; n CPD = 224 ; n cirrhosis = 203 ; n ALT = 2008 ; n AST = 1751 ; n GGT = 1618 
 
 
                                                 
 
